Company overview
Insilico Medicine offers an AI-powered Pharma.AI platform for end-to-end drug discovery, including target identification via PandaOmics, generative molecule design with Chemistry42, and preclinical candidate nomination in 12-18 months. The platform targets diseases in oncology, fibrosis, immunology, neurology, and metabolism, with programs advancing to Phase 2 clinical trials, such as for idiopathic pulmonary fibrosis. It integrates multimodal data for druggable targets, with 95.7% having 3D structures and 86.5% classified as druggable.
Main is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include ai drug discovery, generative ai pharma, target identification, molecule design, pharma.ai platform.
Structured facts
- Website
- https://insilico.com
- Markets served
- United States & Americas
- Keywords
- ai drug discovery, generative ai pharma, target identification, molecule design, pharma.ai platform
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What AI capabilities does Insilico Medicine provide for drug discovery?
- Pharma.AI includes PandaOmics for target prioritization across 38 diseases, Chemistry42 for generative molecule design, and TargetPro for multimodal target identification with high clinical success potential.
- What is the typical timeline for Insilico's preclinical drug candidates?
- From project initiation to preclinical candidate nomination averages 12-18 months, with 60-200 molecules synthesized per program, significantly faster than the traditional 3-6 years.
- In which therapeutic areas and geographies does Insilico operate?
- Focuses on oncology, fibrosis, immunology, neurology, and metabolism; clinical trials conducted in the U.S. and China, with a global pipeline of over 30 programs.
Related editorial coverage
- Verge Rebrands AI Drug Discovery After Trial Setback
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
Explore lab tools and QA/QC resources for R&D teams.
